Segolene Martin

CEO Kantify at KANTIFY

Presenter

Ségolène Martin is CEO and co-founder of Kantify, a Brussels-based biotech using AI to discover new medicines against previously undruggable targets in oncology, CNS, and rare disease.

Kantify's platform, Sapian, integrates target identification with non-structure-based AI-driven small molecule discovery, screening billions of compounds in silico to accelerate the path from hypothesis to preclinical candidate. Combined with advanced multi-parameter optimization and proteome-wide safety prediction, Sapian delivers IP-free, selective molecules designed for reduced off-target risk.

Since its founding, the company has delivered first-in-class modulators for targets considered intractable by conventional methods, at a fraction of the typical timeline and cost.